Determination of the optimal time for radioiodine therapy in anaplastic thyroid carcinoma using the adenovirus-mediated transfer of sodium iodide symporter gene

So,Young; Lee,Yong  Jin; Lee,Won  Woo; Chung,June-Key

doi:10.3892/or.2013.2277

Determination of the optimal time for radioiodine therapy in anaplastic thyroid carcinoma using the adenovirus-mediated transfer of sodium iodide symporter gene

Authors:
- Young So
- Yong Jin Lee
- Won Woo Lee
- June-Key Chung
View Affiliations

Affiliations: Department of Nuclear Medicine, Konkuk University School of Medicine, Chungju, Republic of Korea, Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seoul National University Hospital, Seoul, Republic of Korea
Published online on: February 6, 2013 https://doi.org/10.3892/or.2013.2277
Pages: 1666-1670

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene therapy using human sodium iodide symporter (hNIS) and radioiodine has been considered promising in a variety of gene therapy trials. However, the optimal timing of radioiodine application following hNIS gene transfer remains unknown. The present study aimed to investigate the serial expression of hNIS following adenovirus-mediated hNIS gene transfer into anaplastic thyroid carcinoma (ARO) to determine the optimal timing of radioiodine application. Recombinant adenovirus encoding the hNIS gene (rAd-hNIS) was generated using a homologous recombination reaction. The iodine uptake of rAd-hNIS‑transfected ARO cells gradually increased until 120 min post‑125I application but the fold increase, reflecting the relative uptake of rAd-hNIS‑transfected compared to non‑transfected ARO cells, reached plateau at 60 min post‑125I application. For the in vivo analysis, rAd-hNIS was injected intratumorally into ARO cell xenografts in the thighs of nude mice (n=12). Two, 3, 4 and 6 days after rAd-hNIS injection, γ‑scintigraphic images were obtained 60 min following injection of 5.5 MBq of 131I intraperitoneally. Treated/non-treated (T/NT) xenograft count ratios were the highest at day 2 post‑rAd-hNIS injection (2.85±0.61), and gradually decreased thereafter (2.54±0.65, 2.31±0.42 and 2.18±0.90 at days 3, 4 and 6 post‑rAd-hNIS injection, respectively). Real‑time polymerase chain reaction (RT-PCR) and immunohistochemical staining demonstrated that hNIS expression was the highest at day 2 following rAd-hNIS injection. In conclusion, the optimal timing for radioiodine administration is day 2 after adenovirus-mediated hNIS gene transfer into anaplastic thyroid carcinoma.

View Figures

View References

1	Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI and Saenger EL: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 309:937–941. 1983. View Article : Google Scholar : PubMed/NCBI
2	DeGroot LJ, Kaplan EL, McCormick M and Straus FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 71:414–424. 1990. View Article : Google Scholar : PubMed/NCBI
3	Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
4	Chung JK: Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 43:1188–1200. 2002.PubMed/NCBI
5	Chung JK, Youn HW, Kang JH, Lee HY and Kang KW: Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 44:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
6	Dai G, Levy O and Carrasco N: Cloning and characterization of the thyroid iodide transporter. Nature. 379:458–460. 1996. View Article : Google Scholar : PubMed/NCBI
7	Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL and Jhiang SM: Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun. 226:339–345. 1996. View Article : Google Scholar : PubMed/NCBI
8	Dohan O, De la Vieja A, Paroder V, et al: The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 24:48–77. 2003. View Article : Google Scholar : PubMed/NCBI
9	Boland A, Ricard M, Opolon P, et al: Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 60:3484–3492. 2000.PubMed/NCBI
10	Cho JY, Xing S, Liu X, et al: Expression and activity of human Na⁺/I⁻ symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. 7:740–749. 2000.
11	Spitzweg C, O’Connor MK, Bergert ER, Tindall DJ, Young CY and Morris JC: Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 60:6526–6530. 2000.PubMed/NCBI
12	Cho JY, Shen DH, Yang W, et al: In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther. 9:1139–1145. 2002. View Article : Google Scholar : PubMed/NCBI
13	Schipper ML, Weber A, Behe M, et al: Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res. 63:1333–1338. 2003.PubMed/NCBI
14	Mandell RB, Mandell LZ and Link CJ Jr: Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 59:661–668. 1999.PubMed/NCBI
15	Shimura H, Haraguchi K, Miyazaki A, Endo T and Onaya T: Iodide uptake and experimental ¹³¹I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na⁺/I⁻ symporter gene. Endocrinology. 138:4493–4496. 1997.PubMed/NCBI
16	Smit JW, Shroder-van der Elst JP, Karperien M, et al: Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid. 10:939–943. 2000. View Article : Google Scholar : PubMed/NCBI
17	He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998. View Article : Google Scholar : PubMed/NCBI
18	Spitzweg C, Dietz AB, O’Connor MK, Bergert ER, Tindall DJ, Young CY and Morris JC: In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 8:1524–1531. 2001. View Article : Google Scholar : PubMed/NCBI
19	Lee WW, Moon DH, Park SY, Jin J, Kim SJ and Lee H: Imaging of adenovirus-mediated expression of human sodium iodide symporter gene by 99mTcO4 scintigraphy in mice. Nucl Med Biol. 31:31–40. 2004. View Article : Google Scholar : PubMed/NCBI
20	Huang M, Batra RK, Kogai T, et al: Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Fene Ther. 8:612–618. 2001. View Article : Google Scholar : PubMed/NCBI
21	Zhang L, Sharma S, Zhu LX, et al: Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res. 63:5065–5072. 2003.PubMed/NCBI
22	Dadachova E, Bouzahzah B, Zuckier LS and Pestell RG: Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol. 29:13–18. 2002. View Article : Google Scholar : PubMed/NCBI